Linda Elsegood - The LDN Book, Volume Two: The Latest Research on How Low Dose Naltrexone Could Revolutionize Treatment for PTSD, Pain, IBD, Lyme Disease, Dermatologic Conditions, and More

PRAISE FORThe LDN Book, Volume 2

Since the first volume of The LDN Book was released, I have had the distinct privilege of learning from and collaborating with the best clinicians and researchers in the field of integrative medicine. Through these collaborations, we continue to build upon the already vast applications of this low-dose but high-power medication. I am thrilled to see so many trusted colleagues, who have also become friends, contribute to this important body of work. Thank you, again, Linda Elsegood, for bringing together a tribe of like-minded people who continue to find solutions to challenging medical issues with this simple and inexpensive intervention.

Dr. Nasha Winters, ND, FABNO, author of The Metabolic Approach to Cancer

As a pharmacist, I often wish for a miracle drug that would be safe, effective, and inexpensive and could help the masses take back their health. While no drug is right for everyone, I have seen LDN transform the lives of countless people with autoimmunity. For some, LDN has truly been a miracle drug. I highly recommend both volumes of The LDN Book as valuable resources for patients and clinicians alike to explore the best practices for using LDN.

Dr. Izabella Wentz, Pharm.D., FASCP, New York Times bestselling author of Hashimotos Protocol

A fantastic resource. All the latest research on low dose naltrexone and its various uses in clinical practice is compiled in this easy-to-use volume The LDN Book, Volume 2 . I will definitely be keeping this book in my office for reference.

Jill C. Carnahan, MD, ABIHM, ABoIM, IFMCP

Even if you think you know about the benefits of LDN for certain conditions through practical experience or otherwise, this book will expand your understanding and amazement. It is a remarkable finding that a drug designed for a specific condition can be applied to so many other systems at lower and lower doses. Interestingly, this has shown us that many other drugs may also have unexpected benefits at lower-than-intended doses. There are many layers of complexity that remain to be uncovered!

Dr. Angus Dalgleish, professor of oncology, St. Georges, University of London; principal, Institute for Cancer Vaccines and Immunotherapy (ICVI)

Over the years, a wealth of clinical trials and studies on LDN have given us better information about how and why LDN actually works. Through this research, we have uncovered many new uses of LDN in medical treatment. Reviewing The LDN Book, Volume 2 and seeing how other experts prescribe LDN in their clinics has been a great treat for me. My clinic, Clinic 158, has been prescribing LDN for 12 years. We have thousands of very happy patients who have found success with the medication for a myriad of ailments, and we are still learning new information.

Dr. Andrew McCall, director, Clinic 158

Since inflammation is a major contributor to almost all chronic disorders, LDN therapy bridges nearly every medical specialty. In The LDN Book, Volume 2 , the authors provide an excellent overview of LDNs mechanism of action, review the vast evidence base supporting clinical applications, and, most importantly, report actual cases in which LDN was instrumental in the successful treatment of patients. This book is a must-have for every clinician, and LDN should be considered in the treatment of the many disorders outlined therein.

Sahar Swidan, Pharm.D., R.Ph., ABAAHP, FAARFM, FACA, president and CEO, Pharmacy Solutions

The
LDN
Book

VOLUME TWO

The Latest Research on How

L OW D OSE N ALTREXONE
Could Revolutionize Treatment for PTSD, Pain, IBD, Lyme Disease, Dermatologic Conditions, and More

EDITED BY

Linda Elsegood

FOREWORD BY Dr. Phil Boyle

Chelsea Green Publishing

White River Junction, Vermont

London, UK

Copyright 2020 by The LDN Research Trust.

All rights reserved.

No part of this book may be transmitted or reproduced in any form by any means without permission in writing from the publisher.

Project Manager: Alexander Bullett

Project Editor: Michael Metivier

Developmental Editor: Natalie Wallace

Copy Editor: Laura Jorstad

Proofreader: Diane Durrett

Indexer: Linda Hallinger

Designer: Melissa Jacobson

Page Layout: Abrah Griggs

Printed in Canada.

First printing September 2020.

10 9 8 7 6 5 4 3 2 120 21 22 23 24

Our Commitment to Green Publishing

Chelsea Green sees publishing as a tool for cultural change and ecological stewardship. We strive to align our book manufacturing practices with our editorial mission and to reduce the impact of our business enterprise in the environment. We print our books and catalogs on chlorine-free recycled paper, using vegetable-based inks whenever possible. This book may cost slightly more because it was printed on paper that contains recycled fiber, and we hope youll agree that its worth it. The LDN Book, Volume 2 was printed on paper supplied by Marquis that is made of recycled materials and other controlled sources.

Library of Congress Cataloging-in-Publication Data

Names: Elsegood, Linda, 1956- editor.

Title: The LDN book. Volume 2. The latest research on how low dose naltrexone could revolutionize treatment for PTSD, pain, IBD, Lyme disease, dermatologic conditions, and more / edited by Linda Elsegood.

Other titles: Latest research on how low dose naltrexone could revolutionize treatment for PTSD, pain, IBD, Lyme disease, dermatologic conditions, and more

Description: White River Junction, Vermont : Chelsea Green Publishing, [2020] | Includes bibliographical references and index.

Identifiers: LCCN 2020026302 (print) | LCCN 2020026303 (ebook) | ISBN 9781603589901 (paperback) | ISBN 9781603589918 (ebook)

Subjects: MESH: Naltrexonetherapeutic use | Naltrexonepharmacology | Dose-Response Relationship, Drug | Narcotic Antagoniststherapeutic use | Opioid Peptidesmetabolism

Classification: LCC RM328 (print) | LCC RM328 (ebook) | NLM QV 89 | DDC 615.1/9dc23

LC record available at https://lccn.loc.gov/2020026302

LC ebook record available at https://lccn.loc.gov/2020026303

Chelsea Green Publishing

85 North Main Street, Suite 120

White River Junction, Vermont USA

Somerset House

London, UK

www.chelseagreen.com

To my late mother, who was the best mum in the world!

CONTENTS

by Dr. Phil Boyle

by Linda Elsegood

by J. Stephen Dickson

by Sarah J. Zielsdorf and Neel D. Mehta

by Leonard B. Weinstock and Kristen Blasingame

by Apple Bodemer

by Kirsten Singler

CHAPTER SIX
Pediatrics

by Vivian F. DeNise

CHAPTER SEVEN
Womens Health

by Olga L. Cortez

CHAPTER EIGHT
Traumatic Brain Injury

by Sarah J. Zielsdorf

CHAPTER NINE
Dissociative Disorders

by Wiebke Pape

CHAPTER TEN
Post-Traumatic Stress Disorder

by Ulrich Lanius and Galyn Forster

CHAPTER ELEVEN
Lyme Disease and Other Tick-Borne Illnesses

by Darin Ingels

by Jill Cottel

APPENDIX
Dosing Protocols

by Sarah J. Zielsdorf

In the fields of observation chance favours only the prepared mind.

L OUIS P ASTEUR (18221895)

How does a fertility doctor (or any doctor) become a low-dose naltrexone prescriber? Quite by chance, at least in my case. In 2002 my sisters husband was diagnosed with progressive multiple sclerosis (MS). He was prescribed LDN by Dr. Bernard Bihari, a neurologist in New York credited with discovering the immune-modifying effects of LDN, and his MS stabilized after just a few weeks. About nine months later I attended a small meeting in Galway, Ireland, presented by Robert, an MS patient who had had a similarly miraculous response to LDN treatment. His testimony was striking. He had poor mobility, extreme fatigue, and brain fog with progressive deteriorationuntil he started LDN. His story made a deep impression on me. I was excited to hear how effective this treatment could be for autoimmunity. I decided I would recommend LDN if I had an infertility patient with an autoimmune condition. But first, I needed to find out more about this interesting medication. At that time, the LDN Research Trust did not exist, and there was very little to find in peer-reviewed publications.